Sector News

US priority review for AZ’ Brilinta/aspirin combination

July 13, 2020
Life sciences

The US Food and Drug Administration has agreed to a speedy review of AstraZeneca’s Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who have experienced an acute ischaemic stroke or transient ischaemic attack (TIA).

The marketing application is based on data from the Phase III THALES trial, which showed aspirin plus Brilinta 90mg used twice daily for 30 days resulted in a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.

“Patients who have had an acute ischaemic stroke or transient ischaemic attack are at high risk of experiencing a subsequent stroke, which may be disabling or fatal. [The] Priority Review reflects Brilinta’s potential as a much-needed treatment option to reduce the rate of subsequent stroke for these patients and we look forward to working with the FDA to make Brilinta available as soon as possible,” commented Mene Pangalos, executive vice president, BioPharmaceuticals R&D, at AZ.

Specific data from the trial have not yet been shared, but are to be published in a peer reviewed journal and presented at an forthcoming medical congress, AZ noted.

Brilinta is approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.

An approval in combination with aspirin to prevent a second stroke would significantly expand the drug’s reach.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach